FDA Clears Casgevy for Sickle Cell in Ages 2+, Vertex Shares Surge
VRTX•VRTX•VRTX•VRTX•FDA approval extends Casgevy use to sickle cell patients aged two and older, lowering the minimum treatment age from 12 and broadening the pediatric eligibility. Vertex and CRISPR shares surged on the expanded label, boosting expectations for accelerated enrollment and higher long-term revenue potential.
The FDA has extended Casgevy's approval to include children aged two and above with sickle cell disease, reducing the minimum treatment age from 12. This decision validates the therapy’s safety and efficacy in younger cohorts and broadens the addressable patient population.
Shares of Vertex and its partner CRISPR Therapeutics surged following the pediatric label expansion as investors adjusted forecasts for faster enrollment and revenue acceleration. The authorization paves the way for earlier treatment initiation and strengthens Casgevy’s long-term sales outlook.
